InsidersTradesSigma
Follow the 拓新药业 stock price and the full management transaction log of the company, a listed issuer based in China. Shares trade on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 拓新药业 has published 11 insider filings. Market capitalisation: €2.9bn. The latest transaction was filed on 3 September 2026 (Purchase). Among the most active insiders: 蔡玉瑛. The full history is accessible without an account.
11
Insider Decl.
n/a
Thresholds
€1,482
1 ops.
Buy Volume
€9m
10 ops.
Sell Volume
21Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,232 of 29,063 companies
25.1
score / 100
Value28
Quality23
FCF yld-2.4%
Earn yld-2.4%
EV/EBITDA·
ROE-5.3%
Gross mgn26%
Net mgn-18%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations11 total
11 of 11 declarations
Acerca de 拓新药业
拓新药业 es una empresa del sector de la salud y farmacéutico, que cotiza en el mercado XSHE. Se centra en el desarrollo y la comercialización de medicamentos innovadores.